JPMorgan Chase & Co. Acquires 1,083,492 Shares of agilon health, inc. (NYSE:AGL)

JPMorgan Chase & Co. raised its holdings in agilon health, inc. (NYSE:AGL) by 326.4% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,415,419 shares of the company’s stock after acquiring an additional 1,083,492 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.34% of agilon health worth $5,563,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of AGL. Rhumbline Advisers boosted its stake in shares of agilon health by 24.3% during the second quarter. Rhumbline Advisers now owns 433,019 shares of the company’s stock valued at $2,832,000 after purchasing an additional 84,573 shares during the period. XTX Topco Ltd purchased a new stake in agilon health in the 2nd quarter valued at about $211,000. Simplify Asset Management Inc. bought a new position in agilon health in the 2nd quarter worth about $659,000. Ensign Peak Advisors Inc increased its position in shares of agilon health by 43.5% during the second quarter. Ensign Peak Advisors Inc now owns 140,937 shares of the company’s stock worth $922,000 after acquiring an additional 42,750 shares during the period. Finally, Bank of Montreal Can purchased a new position in shares of agilon health during the second quarter worth approximately $404,000.

agilon health Stock Performance

Shares of AGL stock opened at $2.97 on Friday. agilon health, inc. has a 12-month low of $1.50 and a 12-month high of $7.73. The business’s fifty day simple moving average is $2.07 and its 200-day simple moving average is $3.67. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.06. The company has a market cap of $1.22 billion, a PE ratio of -3.15 and a beta of 0.53.

agilon health (NYSE:AGL) last announced its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.19). agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. The business had revenue of $1.45 billion for the quarter, compared to analysts’ expectations of $1.47 billion. During the same quarter last year, the firm earned ($0.06) earnings per share. Analysts expect that agilon health, inc. will post -0.59 earnings per share for the current fiscal year.

Insider Activity

In related news, Director John William Wulf purchased 45,000 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was acquired at an average price of $2.18 per share, with a total value of $98,100.00. Following the completion of the acquisition, the director now owns 206,133 shares in the company, valued at approximately $449,369.94. This represents a 27.93 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Diana Mckenzie acquired 12,500 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were bought at an average cost of $2.28 per share, for a total transaction of $28,500.00. Following the completion of the acquisition, the director now directly owns 51,319 shares of the company’s stock, valued at approximately $117,007.32. The trade was a 32.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 90,000 shares of company stock worth $198,100 over the last 90 days. 3.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Barclays dropped their price objective on agilon health from $5.00 to $2.00 and set an “underweight” rating on the stock in a research note on Monday, November 11th. Bank of America lowered agilon health from a “buy” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research note on Wednesday, October 2nd. Citigroup raised shares of agilon health from a “sell” rating to a “neutral” rating and upped their price objective for the stock from $1.75 to $2.25 in a research note on Friday, January 10th. Macquarie assumed coverage on shares of agilon health in a research report on Monday, December 16th. They set a “neutral” rating and a $3.00 target price on the stock. Finally, William Blair cut shares of agilon health from an “outperform” rating to a “market perform” rating in a research report on Friday, November 8th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $4.03.

agilon health Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.